Isn't Brilinta ...... brilliant!?

AstraZeneca presented previously announced Phase III data at the European Society of Cardiology Congress showing that experimental antiplatelet agent Brilinta (ticagrelor) significantly reduced cardiovascular events in patients with acute coronary syndromes (ACS), compared with sanofi-aventis and Bristol-Myers Squibb's Plavix (clopidogrel). Cardiologist Douglas Weaver, a past president of the American College of Cardiology, remarked that Brilinta "will become the new standard of care." Full story